📰 Beigene News
Page 10 - Beigene News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Beigene. Real-time updates on events, politics, business and more.
May 10, 2023
BeiGene, Ltd. (NASDAQ:BGNE – Get Rating) has been assigned an average recommendation of “Moderate Buy” from the nine research firms that are presently covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 12-month price objective among […]
May 9, 2023
The PD-1 and PD-L1 inhibitors market is anticipated to be driven in the coming years due to the rise in novel drugs and therapies and the increase in healthcare spending across the world. In
May 7, 2023
Van ECK Associates Corp grew its holdings in shares of BeiGene, Ltd. (NASDAQ:BGNE – Get Rating) by 68.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 92,951 shares of the company’s stock after acquiring an additional 37,698 shares during the period. Van […]
May 6, 2023
BeiGene (NASDAQ:BGNE – Get Rating) posted its earnings results on Thursday. The company reported ($3.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.66) by $0.32, Briefing.com reports. The firm had revenue of $447.80 million during the quarter, compared to analysts’ expectations of $449.44 million. BeiGene had a negative net margin […]
May 6, 2023
BRUKINSA is approved for first-line treatment for CLL/SLL and WM in China and has multiple approved indications in more than 65 markets worldwide BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235),
May 6, 2023
BRUKINSA is approved for first-line treatment for CLL/SLL and WM in China and has multiple approved indications in more than 65 markets worldwide ... | May 6, 2023
May 5, 2023
BeiGene (NASDAQ:BGNE – Get Rating) posted its earnings results on Thursday. The company reported ($3.34) earnings per share for the quarter, topping the consensus estimate of ($3.66) by $0.32, Briefing.com reports. The firm had revenue of $447.80 million for the quarter, compared to analyst estimates of $449.44 million. BeiGene had a negative return on equity […]
May 4, 2023
Recorded first quarter product revenue of $410.3 million, increasing 56.9% over $261.6 million from the prior-year period Launched BRUKINSA in the U.S. for adult patients with chronic lymphocytic
May 4, 2023
Recorded first quarter product revenue of $410.3 million, increasing 56.9% over $261.6 million from the prior-year period Launched BRUKINSA® in the U.S. for adult patients with chronic... | May 4, 2023
May 3, 2023
100% Tumor Shrinkage at 2-months in advanced metastatic colorectal cancer was demonstrated by IMX-110 + BeiGene / Novartis anti-PD-1 Antibody Tislelizumab combination in the first, lowest dose cohort ... | May 3, 2023